All In Biotech

Drug Trial Radar · NCT04040322

Intravenous Iloprost in Subjects With Symptomatic Raynaud's Phenomenon Secondary to Systemic Sclerosis (Phase 3)

A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Phase 3 Study Evaluating the Safety and Efficacy of Intravenous Iloprost in Subjects With Systemic Sclerosis Experiencing Symptomatic Digital Ischemic Episodes (AURORA Study)

Last checked: Nov 20, 2026Latest source record: May 25, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 198 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

198

Actual

Start

Oct 14, 2019

Primary completion

Jun 9, 2021

Study completion Jun 9, 2021

Sponsor

Lead sponsor
Civi Biopharma, Inc.Industry
Sponsor type
Industry
First posted
Jul 31, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase 3, multicenter, double-blind, randomized, placebo-controlled study to evaluate the safety and efficacy of iloprost on the frequency of and relief from symptomatic digital ischemic episodes in subjects with systemic sclerosis.

Conditions

  • Raynaud's Phenomenon Secondary to Systemic Sclerosis

Interventions

  • Placebo IV infusionDrug

    Study drug will be initiated at a starting dose of 0.5 ng/kg/min up to 2.0 ng/kg/min. Subjects will receive study drug for 5 consecutive days as an IV infusion over 6 hours each day via a peripheral line.

  • Iloprost Injection, for intravenous useDrug

    Study drug will be initiated at a starting dose of 0.5 ng/kg/min up to 2.0 ng/kg/min. Subjects will receive study drug for 5 consecutive days as an IV infusion over 6 hours each day via a peripheral line.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in Frequency of Symptomatic RP AttacksTime frame: From baseline (Day 10 to Day 25 of screening period) to the end ofthe efficacy follow-up (Day 8 to Day 21).

Locations

30 sites in 1 country. Site status is shown where the registry gives one.

  • Arizona Arthritis & Rheumatology Research, PLLC

    Phoenix, Arizona

  • Mayo Clinic - Scottsdale

    Scottsdale, Arizona

  • University of Arizona - Arthritis Research Center

    Tucson, Arizona

  • Cedars-Sinai Medical Center

    Los Angeles, California

  • University of California, Los Angeles Medical Center

    Los Angeles, California

  • Stanford University Medical Center

    Palo Alto, California

  • University of California San Francisco

    San Francisco, California

  • Georgetown University Medical Center - Department of Rheumatology

    Washington D.C., District of Columbia

  • Northwestern Medical Faculty Foundation

    Chicago, Illinois

  • University Medical Center New Orleans

    New Orleans, Louisiana

  • Johns Hopkins University School of Medicine

    Baltimore, Maryland

  • Tufts Medical Center

    Boston, Massachusetts

  • University of Michigan

    Ann Arbor, Michigan

  • West Michigan Rheumatology PLLC

    Grand Rapids, Michigan

  • University of Minnesota Maple Grove

    Minneapolis, Minnesota

  • University of Nebraska Medical Center

    Omaha, Nebraska

  • Robert Wood Johnson Medical School

    New Brunswick, New Jersey

  • Hospital for Special Surgery

    New York, New York

  • Columbia University Medical Center

    New York, New York

  • University of Cincinnati - Scleroderma Center

    Cincinnati, Ohio

  • Cleveland Clinic

    Cleveland, Ohio

  • Ohio State University

    Columbus, Ohio

  • The University of Toledo Medical Center (UTMC) - Ruppert Health Center

    Toledo, Ohio

  • University of Pennsylvania

    Philadelphia, Pennsylvania

  • University of Pittsburgh Medical Center

    Pittsburgh, Pennsylvania

  • Medical University of South Carolina (MUSC)

    Charleston, South Carolina

  • University of Texas Houston - Division of Rheumatology and Clinical Immunogenetics

    Houston, Texas

  • University of Utah

    Salt Lake City, Utah

  • Virginia Mason Medical Center

    Seattle, Washington

  • Froedtert Hospital and the Medical College of Wisconsin

    Milwaukee, Wisconsin

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.